Lameditech Launches IOFILL and Plans Laser-Combined Procedures
Lameditech launched the human-derived acellular dermal matrix product IOFILL and is developing a procedure program that combines the material with its laser technology.
This article was automatically drafted and passed editorial compliance checks. It synthesizes public source metadata and is not a substitute for individual care or clinical review.
Laser medical and aesthetic device company Lameditech launched IOFILL on October 19, 2026, expanding its business into regenerative medicine materials. IOFILL is an extracellular matrix product based on human-derived acellular dermal matrix, which is made by removing cellular components from human dermal tissue.
The company is pairing the product launch with development of a treatment program that uses its laser devices. The strategy moves beyond administering an extracellular matrix material alone by combining the material and laser technology within a procedure plan.
What the launch establishes
Lameditech has formally introduced IOFILL as a human-derived acellular dermal matrix-based extracellular matrix product. The company also identified laser integration as a central part of the procedure program it is developing.
How to interpret the treatment concept
The launch and development plan establishes the product concept, not clinical efficacy or safety outcomes. Assessing potential patient benefit and risk requires separate clinical evidence about the material, the laser procedure, and their combined use.
Frequently asked questions
What is IOFILL made from?
IOFILL is an extracellular matrix product based on human-derived acellular dermal matrix, a material produced by removing cellular components from human dermal tissue.
How is IOFILL intended to be combined with lasers?
Lameditech is developing a procedure program that links IOFILL with its laser technology, moving beyond administration of the extracellular matrix material alone.
Is IOFILL effectiveness established by this launch?
No clinical efficacy conclusion can be drawn from a product launch or development plan alone. Evaluating benefit and risk requires separate clinical evidence for IOFILL, the laser procedure, and their combined use.
Questions to ask before considering the procedure
- What clinical evidence supports using IOFILL with the proposed laser procedure?
- What benefits and risks are associated with the material, the laser, and their combined use?
MediIndex articles are for general information only and are not medical advice, diagnosis, or advertising. Outcomes vary by individual — consult a board-certified specialist for personal decisions.
